Trinity Biotech (TRIB) Depreciation & Amortization (CF) (2021 - 2024)

Trinity Biotech has disclosed Depreciation & Amortization (CF) across 4 years of filings, most recently posting $317000.0 for Q4 2024.

• Depreciation & Amortization (CF) for Q4 2024 came in at $317000.0, up 15750.0% year-over-year; the trailing twelve-month figure through Dec 2025 was $317260.0 (changed 0.03% YoY), and the FY2025 annual result was $1.4 million, up 16.39% from the prior year.
• Depreciation & Amortization (CF) came in at $317000.0 for Q4 2024 at Trinity Biotech, up from $260.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $478000.0 in Q3 2022 to a low of -$65.0 in Q2 2024.
• The 4-year median for Depreciation & Amortization (CF) is $351.0 (2023), against an average of $107524.0.
• Peak annual rise in Depreciation & Amortization (CF) reached 15750.0% in 2024, while the deepest fall reached 121.31% in 2024.
• Trinity Biotech's Depreciation & Amortization (CF) stood at $146000.0 in 2021, then surged by 210.27% to $453000.0 in 2022, then sank by 99.56% to $2000.0 in 2023, then soared by 15750.0% to $317000.0 in 2024.
• The last three Depreciation & Amortization (CF) figures came in at $317000.0 (Q4 2024), $260.0 (Q3 2024), and -$65.0 (Q2 2024), per Business Quant data.